136630-39-2
Chemical Structure
2,7-Dibromocarbazole
Synonym(s): 2,7-DBCZ
- CAS No.: 136630-39-2
- Formula:C12H7Br2N
- Molecular Weight:325.00
IUPAC Name: 2,7-dibromo-9H-carbazole
InChIKey: QPTWWBLGJZWRAV-UHFFFAOYSA-N
SMILES: BrC1=CC2=C(C=C1)C3=C(C=C(Br)C=C3)N2
Biological Activity: 2,7-Dibromocarbazole (2,7-DBCZ) is an orally active AhR agonist and MAOB inhibitor that can cross the blood-brain barrier. 2,7-Dibromocarbazole induces CYP1A/CYP1B1, developmental toxicity and oxidative toxicity, Akt phosphorylation, apoptosis, mitochondrial depolarization, and calcium elevation. 2,7-Dibromocarbazole disrupts dopamine homeostasis, promotes α-synuclein aggregation and transcriptomic dysregulation, leading to hepatic lipid accumulation, liver lesions, brain injury, and angiogenesis/energy metabolism disorders, while activating ERα and inhibiting GRα. 2,7-Dibromocarbazole can be used in research on cardiotoxicity and Parkinson's disease[1][2][3][4][5][6][7][8].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
2,7-Dibromocarbazole | 99.96% | 2,7-Dibromocarbazole (2,7-DBCZ) is an orally active AhR agonist and MAOB inhibitor that can cross the blood-brain barrier. 2,7-Dibromocarbazole induces CYP1A/CYP1B1, developmental toxicity and oxidative toxicity, Akt phosphorylation, apoptosis, mitochondrial depolarization, and calcium elevation. 2,7-Dibromocarbazole disrupts dopamine homeostasis, promotes α-synuclein aggregation and transcriptomic dysregulation, leading to hepatic lipid accumulation, liver lesions, brain injury, and angiogenesis/energy metabolism disorders, while activating ERα and inhibiting GRα. 2,7-Dibromocarbazole can be used in research on cardiotoxicity and Parkinson's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ji C, et al. AhR agonist activity confirmation of polyhalogenated carbazoles (PHCZs) using an integration of in vitro, in vivo, and in silico models. Environmental science & technology. 2019 Dec 17;53(24):14716-23.
- [2]. Ji C, et al. Conformation of CD40LG and ANXA5 as Key Events of 2, 7-Dibromocarbazole-Induced Cardiotoxicity Using in Vivo and in Vitro Models. Environmental Science & Technology. 2026 Jan 29;60(5):3911-21.
- [3]. Lu X, et al. Integrated New Approach Methodologies Reveal the Potential Role of 2,7-Dibromocarbazole in Parkinson's Disease via Monoamine Oxidase B Inhibition and Dopaminergic Dysfunction. Environmental science & technology. 2026 Mar 10;60(9):7159-7170.
- [4]. Huang M, et al. Tissue-specific accumulation, depuration and histopathological effects of 3,6-dichlorocarbazole and 2,7-dibromocarbazole in adult zebrafish (Danio rerio). Aquatic toxicology (Amsterdam, Netherlands). 2024 Jan;266:106803.
- [5]. Zhou W, et al. Endocrine Disruptor 2,7-Dibromocarbazole Disrupts Energy Metabolism and Alters Locomotor Behavior in Juvenile Zebrafish. Chemical research in toxicology. 2026 Apr 20;39(4):614-623.
- [6]. Ji C, et al. 2,7-Dibromocarbazole interferes with tube formation in HUVECs by altering Ang2 promoter DNA methylation status. The Science of the total environment. 2019 Dec 20;697:134156.
- [7]. Ji C, et al. Evaluation of the developmental toxicity of 2,7-dibromocarbazole to zebrafish based on transcriptomics assay. Journal of hazardous materials. 2019 Apr 15;368:514-522.
